All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The role of new technologies in myeloproliferative neoplasms: Application of next-generation sequencing in myelofibrosis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F21%3AN0000222" target="_blank" >RIV/00098892:_____/21:N0000222 - isvavai.cz</a>

  • Alternative codes found

    RIV/61989592:15110/21:73608216

  • Result on the web

    <a href="http://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.13504" target="_blank" >http://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.13504</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/ijlh.13504" target="_blank" >10.1111/ijlh.13504</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    The role of new technologies in myeloproliferative neoplasms: Application of next-generation sequencing in myelofibrosis

  • Original language description

    Introduction: Driver mutations in Philadelphia chromosome-negative myeloproliferative neoplasms are well known. In the past, whole-genome sequencing identified nondriver mutations in other genes, potentially contributing to evolution of malignant clones. Methods: Next-generation sequencing was used to assess the presence of any mutations in 14 candidate genes at the point of diagnosis and the resultant impact on the clinical course of the disease. Results: The study analysed 63 patients with myelofibrosis (MF). Nondriver mutations were detected in 44% of them. The most frequently affected genes were ASXL1 (27%), TET2 (11%) and SF3B1 (6%). The frequency of such mutations was highest in primary MF (59%) and lowest in the prefibrotic phase of primary MF (21%). Patients with prognostically unfavourable sequence variants in genes had significantly worse overall survival (53 vs 71 months; HR = 2.77; 95% CI 1.17-6.56; P =.017). Conclusion: In our study, multivariate analysis proved DIPSS to be the only significant factor to predict patient survival. DIPSS contains all of the important clinical and laboratory factors except genetic changes. Stratification of patients according to DIPSS is still beneficial although there are newer and improved scoring systems like GIPSS or MIPSS70. Assessing subclonal mutations in candidate genes during diagnosis may aid in the identification of high-risk MF patients and is therefore relevant for making a prediction for overall survival more accurate.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    International Journal of Laboratory Hematology

  • ISSN

    1751-5521

  • e-ISSN

    1751-553X

  • Volume of the periodical

    43

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    8

  • Pages from-to

    1070-1077

  • UT code for WoS article

    000630033100001

  • EID of the result in the Scopus database

    2-s2.0-85102616772